Riskpilot← Back to searchSign inGet full accessRegSmart Medtech AB
ABActiveOrg 5594228073Eklundshovsvägen 5Research and experimental development on natural sciences and engineering · NACE 7210Est. 20235 employees
Revenue 2024
SEK 8,7M
+264% vs 2023
EBITDA margin
14.3%
+357% vs 2023
Equity ratio
48.3%
Financial strength
Net profit 2024
SEK 751K
+369% vs 2023
| Revenue | SEK 8,7M | +264% |
| EBITDA | SEK 1,2M | +357% |
| Net profit | SEK 751K | +369% |
| Total assets | SEK 4M | +66% |
| Equity | SEK 1,9M | +63% |
| Employees | 5 | — |
Legal name
RegSmart Medtech AB
Org number
5594228073
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 februari 2023
Share capital
SEK 25 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av Larhed, Agneta Maria Meyer, Karin Judith Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva konsultverksamhet inom forskning på läkemedelsområdet och inom medicinska tekniska området samt därmed förenlig verksamhet.
Address
Eklundshovsvägen 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 2 393 | 8 704 |
| Staff expenses | — | — |
| EBITDA | 272 | 1 244 |
| Depreciation & amort. | −0 | −0 |
| EBIT | 272 | 1 244 |
| Net financials | — | 23 |
| Profit before tax | 203 | 948 |
| Tax | −43 | −197 |
| Net profit | 160 | 751 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 2 412 | 4 010 |
| Equity | 1 185 | 1 936 |
| Long-term debt | 0 | 0 |
| Short-term debt | 1 158 | 1 686 |
| Total debt | 1 158 | 1 686 |
EBITDA margin
14.3%
This company
15.8%
Market median
-9% vs market
20232024
Equity ratio
48.3%
This company
38.2%
Market median
+26% vs market
20232024
Return on equity
38.8%
This company
18.4%
Market median
+111% vs market
20232024
Net profit margin
8.6%
This company
8.1%
Market median
+6% vs market
20232024
Asset turnover
2.17×
This company
1.12×
Market median
+94% vs market
20232024
Debt / equity
1.07×
This company
0.62×
Market median
-73% vs market
20232024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-02-01 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MI Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
SA Chief Auditor | Chief Auditor | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
RegSmart Life Science AB | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Center for Translational Research Sweden ABRegSmart Life Science AB
RegSmart Medtech AB (this company)Board members of RegSmart Medtech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Ivan Högberg | Chief Executive Officer | 0 companies |
| Stéphanie Anna Chantal Ljungberg | Chief Auditor | 0 companies |
| Karin Judith Meyer | Board of Directors | 0 companies |
| Agneta Maria Larhed | Chairman | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Marie Christina Gårdmark | Board of Directors | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |